Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer

Sherko Kuemmel, Joerg Heil, S. Bruz̆as, +21

JAMA Surgery

Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany

Mattea Reinisch, S. Bruz̆as, Jennifer Spoenlein, +8

Therapeutic Advances in Medical Oncology

Using the framework of corporate culture in “mergers” to support the development of a cultural basis for integrative medicine – guidance for building an integrative medicine department or service

Claudia M. Witt, Marion Pérard, Brian Berman, +14

Patient Preference and Adherence

Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant

Sherko Kuemmel, Hakima Harrach, Rita K. Schmutzler, +5

npj Breast Cancer

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

Sherko Kuemmel, Carlo Tondini, Jacinta Abraham, +13

Breast Cancer Research and Treatment

Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice

S. Bruz̆as, Sherko Kuemmel, Hakima Harrach, +8

Cancers

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer

Nadia Harbeck, Raquel von Schumann, Ronald Kates, +17

Cancers

Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Hans Wildiers, Anne Armstrong, Eveline Cuypere, +17

Clinical Cancer Research

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial

Monika Graeser, Oleg Gluz, Claudia Biehl, +24

Clinical Cancer Research

Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel

Bolivar Arboleda-Osorio, Rupert Bartsch, Evandro de Azambuja, +9

The Oncologist